14,645 results match your criteria burkitt's lymphoma


B Cell Lymphomas of the GI Tract.

Curr Gastroenterol Rep 2021 May 8;23(7). Epub 2021 May 8.

Division of Hematology/Oncology, Northwestern University, Chicago, IL, USA.

Purpose Of The Review: Primary GI lymphomas of B cell origin are a diverse group of lymphomas. In this article, we provide an overview of the diagnosis, pathologic and molecular features, and management of these varied lymphomas.

Recent Findings: The most common primary GI lymphomas are diffuse large B cell lymphoma (DLBCL) and marginal zone lymphomas (MZL), but follicular lymphomas (FL), mantle cell lymphomas (MCL), post-transplant lymphoproliferative disorders (PTLD), and Burkitt lymphoma of the GI tract also occur. Read More

View Article and Full-Text PDF

PARP1 Is Overexpressed in Hematological Malignant Cell Lines: A Framework for Experimental Oncology.

Anticancer Res 2021 May;41(5):2397-2402

Pharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Department of Physiology and Pharmacology, Federal University of Ceará, Fortaleza, Brazil.

Background/aim: Experimental oncology commonly uses cells as oncological models, providing a framework for the testing of drugs, and investigation of cytotoxicity, mutagenesis and carcinogenesis. Investigations into poly-ADP-ribose polymerase 1 (PARP1) inhibition have become ever more relevant due to its approval as a therapeutic option for tumors with BRCA1/2 DNA repair-associated mutation and the seemingly high PARP expression levels in some tumor subtypes. In this study, we aimed to determine PARP1 gene expression of different hematological cancer-derived cell lineages and compare them to that of normal cell lines. Read More

View Article and Full-Text PDF

MAP-kinase and JAK-STAT pathways dysregulation in plasmablastic lymphoma.

Haematologica 2021 May 6. Epub 2021 May 6.

Hematopathology Unit, Hospital Clínic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid.

Plasmablastic lymphoma (PBL) is an aggressive B-cell lymphoma with an immunoblastic/large cell morphology and plasmacytic differentiation. The differential diagnosis with Burkitt lymphoma (BL), plasma cell myeloma (PCM) and some variants of diffuse large B-cell lymphoma (DLBCL) may be challenging due to the overlapping morphological, genetic and immunophenotypic features. Furthermore, the genomic landscape in PBL is not well known. Read More

View Article and Full-Text PDF

Burkitt lymphoma with granulomatous reaction: A M1/TH1-polarized microenvironment associates with controlled growth and spontaneous regression.

Histopathology 2021 May 5. Epub 2021 May 5.

Department of Medical Biotechnologies, University of Siena, Siena, Italy.

Aims: Burkitt lymphoma (BL) is an aggressive B-cell lymphoma, which in some instances, may show a granulomatous reaction associated with a favourable prognosis and occasional spontaneous regression. In the present study, we aimed to define the tumour microenvironment (TME) in four of such cases, two of which regressed spontaneously.

Methods And Results: All cases showed aggregates of tumour cells with the typical morphology, molecular cytogenetics and immunophenotype of BL surrounded by a florid epithelioid granulomatous reaction. Read More

View Article and Full-Text PDF

Selenium nanoparticles: Synthesis, cytotoxicity, antioxidant activity and interaction studies with ct-DNA and HSA, HHb and Cyt c serum proteins.

Biotechnol Rep (Amst) 2021 Jun 15;30:e00615. Epub 2021 Apr 15.

Center of Medical Biology Research, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.

The aim of this study was the synthesis of selenium nanoparticles (SeNPs) employing vitamin C as a biocompatible and low toxic reducing agent. The synthesized selenium nanoparticles were characterized by using UV-vis, FT-IR, SEM-EDX, TEM, DLS, and zeta potential measurements. The results of the DPPH free radical scavenging assay demonstrate that this synthesized nano-selenium has strong potentials to scavenge the free radicals and cytotoxicity against MCF-7 and Raji Burkitt's lymphoma cancer cell lines. Read More

View Article and Full-Text PDF

Chemotherapy Treatments for Burkitt Lymphoma: Systematic Review of Interventional Studies.

Clin Lymphoma Myeloma Leuk 2021 Apr 3. Epub 2021 Apr 3.

Pharmaceutical Sciences Postgraduate Program, Federal University of Paraná, Curitiba, PR, Brazil; Department of Pharmacy, Federal University of Paraná, Curitiba, PR, Brazil. Electronic address:

Background: Burkitt lymphoma (BL) is an aggressive hematologic cancer. This study synthetized the evidence about the efficacy and safety of chemotherapy treatments used in patients with BL using the World Health Organization classification.

Materials And Methods: A systematic review of interventional studies was performed. Read More

View Article and Full-Text PDF

Severe type-B lactic acidosis in a patient with bilateral renal Burkitt's lymphoma.

Clin Nephrol Case Stud 2021 26;9:49-53. Epub 2021 Apr 26.

Department of Medicine, Nephrology Section, University of Miami Miller School of Medicine/Miami VAMC, and.

Introduction: Lactic acidosis (LA) can be categorized as type A, which occurs in the presence of tissue hypoxia, or type B, occurring in the absence of tissue hypoxia. Hematologic malignancies are an uncommon cause of type B LA.

Case Presentation: A 63-year-old man, HIV-negative, with a history of diabetes mellitus, hypothyroidism, and non-alcoholic fatty liver disease (NAFLD), presented to the ED complaining of acute-on-chronic lumbar pain, and was found to have high serum anion gap (AG) LA. Read More

View Article and Full-Text PDF

Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations.

Cancers (Basel) 2021 Apr 25;13(9). Epub 2021 Apr 25.

Department of Pediatric Hematology, Oncology and BMT, University Hospital Muenster, 48149 Münster, Germany.

Despite poor survival, controversies remain in the treatment for refractory or relapsed pediatric non-Hodgkin lymphoma (r/r NHL). The current project aimed to collect international experience on the re-induction treatment of r/r NHL, hematopoietic stem cell transplantation (HSCT), risk factors associated with outcome, and to suggest treatment recommendations. Inclusion criteria were (i) refractory disease, disease progression or relapse of any NHL subtype except anaplastic large cell lymphoma, (ii) age < 18 years at initial diagnosis, (iii) diagnosis in/after January 2000. Read More

View Article and Full-Text PDF

Minimal Disease Monitoring in Pediatric Non-Hodgkin's Lymphoma: Current Clinical Application and Future Challenges.

Cancers (Basel) 2021 Apr 15;13(8). Epub 2021 Apr 15.

Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.

Minimal residual disease (MRD) detection is established routine practice for treatment stratification in leukemia and used for treatment optimization in adult lymphomas. Minimal disease studies in childhood non-Hodgkin lymphomas are challenged by stratified treatment in different subtypes, high cure rates, low patient numbers, limited initial tumor material, and early progression. Current clinical applications differ between the subtypes. Read More

View Article and Full-Text PDF

Assessment of Mixed   Infection in Endemic Burkitt Lymphoma: A Case-Control Study in Malawi.

Cancers (Basel) 2021 Apr 2;13(7). Epub 2021 Apr 2.

Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Background: Endemic Burkitt lymphoma (eBL) is the most common childhood cancer in Africa and is linked to () malaria infection, one of the most common and deadly childhood infections in Africa; however, the role of genetic diversity is unclear. A potential role of genetic diversity in eBL has been suggested by a correlation of age-specific patterns of eBL with the complexity of infection in Ghana, Uganda, and Tanzania, as well as a finding of significantly higher genetic diversity, based on a sensitive molecular barcode assay, in eBL cases than matched controls in Malawi. We examined this hypothesis by measuring diversity in serine repeat antigen-5 (), an antigenic target of blood-stage immunity to malaria, among 200 eBL cases and 140 controls, all polymerase chain reaction (PCR)-positive, in Malawi. Read More

View Article and Full-Text PDF

Comparison in safety of chemotherapy protocols for blood cancers: toxicity of H-CVAD versus GELA/BURKIMAB/PETHEMA LAL.

Ecancermedicalscience 2021 22;15:1206. Epub 2021 Mar 22.

Haematology Department, Complejo Hospitalario Universitario de Albacete, Calle Hermanos Falcó 37, 02008 Albacete, Spain.

Background And Objective: The Hyper-CVAD/Methotrexate-Cytarabine (H-CVAD/MTX-AraC) chemotherapy protocol has been one of the standard treatments for blood cancers, such as Mantle cell lymphoma (MCL), Burkitt's lymphoma (BL) and B-cell and T-cell acute lymphoblastic leukaemia (ALL). Due to high toxicity, it has been progressively replaced with new specific regimens with a better safety profile (GELA protocol for MCL, BURKIMAB for BL and PETHEMA for B-cell and T-cell ALL). The objective of this study is to analyse the toxicity and infectious complications of these therapeutic regimens, as well as the event free survival (EFS). Read More

View Article and Full-Text PDF

The Construction and Characterization of 1F5 Chimeric Anti-CD20 Monoclonal Antibodies: An Efficient Splicing by Overlap Extension-polymerase Chain Reaction Technique.

Iran J Allergy Asthma Immunol 2021 Apr 17;20(2):205-220. Epub 2021 Apr 17.

Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Despite the unparalleled success of anti-CD20-targeted immunotherapy, the currently available mAbs are not sufficiently efficacious in the treatment of lymphoma. 1F5 is one of a panel of anti-CD20 mAbs that was used in the B-cell lymphoma serotherapy. Despite the efficacy of murine 1F5 mAbs in lymphoma patients, the 1F5 chimeric antibodies with human effector functionality are yet to be approved and widely used in the treatment of lymphoma. Read More

View Article and Full-Text PDF

Excessive elevation of serum phosphate during tumor lysis syndrome: Lessons from a particularly challenging case.

Clin Nephrol Case Stud 2021 16;9:39-44. Epub 2021 Apr 16.

Medicine Service, Ralph H. Johnson VA Medical Center, Charleston, and.

Burkitt's lymphoma is a common cause of tumor lysis syndrome (TLS) and, in the era of aggressive utilization of prophylactic allopurinol and recombinant uricase enzyme, nephrologists are increasingly witnessing monovalent or divalent cation abnormalities without marked uric acid elevation. An 18-year-old male received his 1 cycle of intensive chemotherapy for Burkitt's lymphoma and developed TLS as defined by the Cairo Bishop criteria. Lactate dehydrogenase peaked at 9,105 U/L (range: 130 - 250) and was accompanied by acute kidney injury, including serum creatinine 2. Read More

View Article and Full-Text PDF

Early-stage Burkitt lymphoma remained in remission 7 years from diagnosis after only one cycle of chemoimmunotherapy.

BMJ Case Rep 2021 Apr 20;14(4). Epub 2021 Apr 20.

Hematopathology, Harper University Hospital, Detroit, Michigan, USA.

Burkitt lymphoma (BL) is a rare, mature, fast-growing and highly aggressive B-cell neoplasm. It has a high-proliferation rate with distinctive genetic changes in the C-MYC oncogene. Treatment usually requires intense and frequent chemotherapy regimens with central nervous system prophylaxis as the usual regimens used for other non-Hodgkin's lymphoma yield poor survival in BL. Read More

View Article and Full-Text PDF

Follicular tissue fragments in fine-needle aspiration cytology of lymph nodes: A useful clue in differential diagnosis of follicular lymphoma and reactive follicular hyperplasia.

Diagn Cytopathol 2021 Apr 20. Epub 2021 Apr 20.

Department of Pathology, Showa University School of Medicine, Tokyo, Japan.

Background: In Fine-needle aspiration cytology (FNAC) of lymph nodes, tissue fragments derived from follicular structures may be observed in specimens. We defined such tissue fragments as follicular tissue fragments (FTF), and investigated differences in cytological findings for FTFs of each histological type.

Method: A total of 41 cases with FNAC of lymph nodes were examined. Read More

View Article and Full-Text PDF

Tumor Lysis Syndrome: Introduction of a Cutaneous Variant and a New Classification System.

Cureus 2021 Mar 11;13(3):e13816. Epub 2021 Mar 11.

Center for Personalized Cancer Therapy, University of California San Diego Moores Cancer Center, La Jolla, USA.

Tumor lysis syndrome, an oncological emergency, is characterized by laboratory parameters such as hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia, as well as renal injury with an elevated creatinine. Tumor lysis syndrome is seen in patients with aggressive malignancies and high tumor burden. More frequently, it occurs in individuals with hematologic malignancies such as high-grade lymphomas (such as Burkitt lymphoma) and leukemia (such as acute lymphocytic leukemia). Read More

View Article and Full-Text PDF

B Cell Receptor-Responsive miR-141 Enhances Epstein-Barr Virus Lytic Cycle via FOXO3 Inhibition.

mSphere 2021 Apr 14;6(2). Epub 2021 Apr 14.

Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA

Antigen recognition by the B cell receptor (BCR) is a physiological trigger for reactivation of Epstein-Barr virus (EBV) and can be recapitulated by cross-linking of surface immunoglobulins. Previously, we identified a subset of EBV microRNAs (miRNAs) that attenuate BCR signal transduction and subsequently dampen lytic reactivation in B cells. The roles of host miRNAs in the EBV lytic cycle are not completely understood. Read More

View Article and Full-Text PDF

The role of EBV in hematolymphoid proliferations: Emerging concepts relevant to diagnosis and treatment.

Histopathology 2021 Apr 7. Epub 2021 Apr 7.

Robert J. Tomsich Pathology and Laboratory Medicine Institute, Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH, USA.

Epstein-Barr virus (EBV) is a ubiquitous gammaherpesvirus with >90% of the adult population worldwide harboring latent infection. A small subset of those infected develop EBV-associated neoplasms including a range of lymphoproliferative disorders (LPD). The diagnostic distinction of these entities appears increasingly relevant as our understanding of EBV-host interactions and mechanisms of EBV-driven lymphomagenesis improves. Read More

View Article and Full-Text PDF

Phenotypical Characterization and Clinical Outcome of Canine Burkitt-Like Lymphoma.

Front Vet Sci 2021 17;8:647009. Epub 2021 Mar 17.

Department of Medical Veterinary Science, University of Bologna, Bologna, Italy.

In dogs, Burkitt-like lymphoma (B-LL) is rare tumor and it is classified as a high-grade B-cell malignancy. The diagnosis is challenging because of the similar histologic appearance with other histotypes, no defined phenotypical criteria and poorly described clinical aspects. The aim of the study was to provide a detailed description of clinical and morphological features, as well as immunophenotypical profile of B-LL in comparison with the human counterpart. Read More

View Article and Full-Text PDF

[Research Advances in the Treatment of B-Cell Acute Lymphoblastic Leukemia Based on Surface Antigen Expression --Review].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021 Apr;29(2):648-652

Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, Henan Province,

B-cell acute lymphoblastic leukemia (B-ALL) is a common malignant tumor in hematopoietic system. Although the remission rate of the patients with adult B-ALL is similar to those with childhood B-ALL, the rate of long-term disease-free survival (DFS) rate is significantly lower, once recurrence, the remission rate of routine chemotherapy is low and the prognosis is so poor. Based on the expression of tumor cell surface antigens(such as CD19, CD20 and CD22), the specific monoclonal antibodies, bispecific antibodies and chimeric antigen receptor T cells (CAR-T), and other targeted immunotherapy can greatly improve the efficacy of B-ALL patients, especially for patients with relapse and refractory. Read More

View Article and Full-Text PDF

[Effect of Autophagy to Drug Resistance of B-cell Lymphoma Cells].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021 Apr;29(2):500-507

Department of Hematology, Affiliated Hospital of Southwest Medical University, Luzhou 646000, China,Stem Cell Laboratory Affiliated to Southwest Medical University, Luzhou 646000, China,E-mail:

Objective: To investigate the effect of autophagy on the drug resistance of different human lymphoma cells.

Methods: Human Burkitt's lymphoma cell Daudi, human B lymphoma cell SUDHL-4, and human mantle cell lymphoma cell JeKo-1 were taken as the research subjects. The expression of Atg5 was inhibited by the treatments of autophagy inhibitors or stable interference via lentivirus infection. Read More

View Article and Full-Text PDF

[Effects of Emodin Derivative on Cell Cycle, Apoptosis and NF-κB Pathway in Burkitt Lymphoma Cells].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021 Apr;29(2):474-488

Department of Chemistry, Fuzhou University, Fuzhou 350004, Fujian Province, China.

Objective: To investigate the effect and mechanism of a novel emodin derivative YX-18 on Burkitt lymphoma (BL) cells.

Methods: MTT assay was used to detect the effect of YX-18 on the proliferation of BL cell lines CA46 and Raji. Annexin V-PE/7-AAD double staining assay was used for detecting the effect of YX-18 on the apoptosis of CA46 and Raji cells. Read More

View Article and Full-Text PDF

Lack of expression of LMO2 clone SP51 identifies MYC rearrangements in aggressive large B-cell lymphomas.

Virchows Arch 2021 Apr 3. Epub 2021 Apr 3.

Department of Pathology, Hospital del Mar, Institut Hospital del Mar d'Investigacions Mediques (IMIM), Barcelona, Spain.

MYC rearrangements (MYC-R) confer unfavorable prognosis to large B-cell lymphomas (LBCL). Because of the low incidence of such genetic alteration, surrogates to screen MYC-R may be useful in daily practice. Previous studies suggested that clone 1A9-1 of LMO2 loss may be a good predictor for the presence of MYC-R in LBCL. Read More

View Article and Full-Text PDF

Gigantomastia During Pregnancy Due to Burkitt Lymphoma.

Eur J Breast Health 2021 Jan 24;17(1):76-79. Epub 2020 Dec 24.

Department of Obstetrics and Gynecology, P.O. Santa Maria delle Grazie Asl Napoli 2 Nord, Napoli, Italy.

Gigantomastia is a rare complication of pregnancy usually associated with benign conditions and rarely with malignancies. This paper reports a non-Hodgkin lymphoma case associated with gigantomastia during pregnancy. The patient was a 30-year-old gravida one woman, with a history of rapidly enlarging right breast at 2 weeks prior to presentation. Read More

View Article and Full-Text PDF
January 2021

Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma.

Haematologica 2021 Apr 1. Epub 2021 Apr 1.

Section of Hematology, Department of Medicine, University of Calgary, Calgary, AB.

B-cell non-Hodgkin's lymphoma (B-NHL) encompasses multiple clinically and phenotypically distinct subtypes of malignancy with unique molecular etiologies. Common subtypes of B-NHL such as diffuse large B-cell lymphoma (DLBCL) have been comprehensively interrogated at the genomic level. But rarer subtypes such as mantle cell lymphoma (MCL) remain sparsely characterized. Read More

View Article and Full-Text PDF

[Cell Function Research of β-Trefoil Lectins from Mytilidae].

Authors:
Yuki Fujii

Yakugaku Zasshi 2021 ;141(4):481-488

Laboratory of Functional Morphology, Graduate School of Pharmaceutical Sciences, Nagasaki International University.

Two novel β-trefoil lectins, MytiLec-1 and SeviL were found from mussels in the coast of Yokohama and Nagasaki. MytiLec-1 was purified from gill and mantle of Mytilus galloprovincialis. It was consisted of 149 amino acid residues and there was no similarity with any other proteins when it was discovered. Read More

View Article and Full-Text PDF
January 2021

A Case of a 13-Year-Old Adolescent with Burkitt's Lymphoma Presented With Dysphonia: Common Complaint Yet Uncommon Presentation.

Clin Lymphoma Myeloma Leuk 2021 Mar 4. Epub 2021 Mar 4.

Department of Otolaryngology, Head and Neck Surgery, Rabin Medical Center, Petach Tikva, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

View Article and Full-Text PDF

Role of FNAC in Extramammary Tumors Metastatic to the Breast.

J Cytol 2020 Oct-Dec;37(4):159-165. Epub 2020 Oct 31.

Department of Oncopathology, Gujarat Cancer and Research Institute, Civil Hospital Campus, Asarwa, Ahmedabad, Gujarat, India.

Background: Metastasis to the breast of an extra-mammary origin is very rare. FNAC plays an important role in differentiating non-mammary breast metastasis from primary malignancy. This study aimed to analyze the cytomorphological criteria and its pitfalls in differentiating metastatic lesion of the breast from primary malignancy. Read More

View Article and Full-Text PDF
October 2020

Neurolymphomatosis of the median nerve, optic nerve, L4 spinal nerve root and cauda equina in patients with B-cell malignancies: a case series.

J Med Case Rep 2021 Mar 26;15(1):133. Epub 2021 Mar 26.

Department of Hematology/Oncology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.

Background: Neurolymphomatosis is rare. Neoplastic lymphocytes are seen to invade nerves (cranial or peripheral), nerve roots or other related structures in patients with hematological malignancy. It is a separate entity from central nervous system lymphoma. Read More

View Article and Full-Text PDF